ArticleCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2026
Comparative Outcomes of Transcatheter Versus Surgical Pulmonary Valve Replacement in Adults With Congenital Heart Disease.
Article in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary valve replacement is frequently required in adults with congenital heart disease (CHD). Comparative real-world outcomes between percutaneous transcatheter pulmonary valve implantation (TPVR) and surgical pulmonary valve replacement (SPVR) remain incompletely characterized. We evaluated outcomes and resource utilization for both approaches.
methodsUsing the National Inpatient Sample (2016-2022), we identified adult CHD patients undergoing TPVR or SPVR. The primary outcome was in-hospital mortality. Secondary outcomes included acute kidney injury (AKI), infection, mechanical circulatory support (MCS), and any major complication. Survey-weighted logistic regression assessed associations with outcomes, adjusting for demographics, comorbidities, and hospital factors.
resultsAmong 11,285 hospitalizations (31% TPVR, 69% SPVR), overall mortality was 1.7%. Unadjusted mortality was lower for TPVR (1.0% vs. 2.0%, p = 0.095). After adjustment, there was no significant difference in mortality between the treatment arms (adjusted OR 2.64, 95% CI 0.92-7.61; p = 0.072). However, SPVR was associated with significantly higher odds of AKI (adjusted OR 5.39, p < 0.001), infection (adjusted OR 5.96, p < 0.001), and MCS requirement (adjusted OR 130.3, p < 0.001). Any major complication occurred in 95.5% of SPVR versus 35.4% of TPVR patients (adjusted OR 81.2, p < 0.001). TPVR was associated with significantly shorter LOS (2.8 vs. 9.7 days; adjusted difference -6.1 days, p < 0.001) and lower hospitalization charges ($209,918 vs. $336,655; p < 0.001).
conclusionsIn adults with CHD, TPVR was associated with significantly lower complication rates, shorter hospitalization, and reduced cost compared with surgical replacement. While mortality was low for both, substantial differences in morbidity and resource utilization favor TPVR, highlighting the value of transcatheter options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.